Venus Remedies shares surged 4.73 per cent to Rs 264.65 on licensing pact with a Korean firm, for selling Sulbactomax drug, used in the treatment of pre or post-surgical infection and also for respiratory infections, in South Korea.
The undisclosed Korean Partner would be marketing the drug exclusively for Venus over the life of the patent. Further, the product will be supplied from Venus Baddi Unit. The stock made an intraday high of Rs 279 and a low of Rs 252 with trading volumes of 1.3 lakh shares.
